563 related articles for article (PubMed ID: 20234356)
1. Aldosterone: effects on the kidney and cardiovascular system.
Briet M; Schiffrin EL
Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
[TBL] [Abstract][Full Text] [Related]
2. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.
Joffe HV; Adler GK
Heart Fail Rev; 2005 Jan; 10(1):31-7. PubMed ID: 15947889
[TBL] [Abstract][Full Text] [Related]
3. Vascular actions of aldosterone.
Briet M; Schiffrin EL
J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
[TBL] [Abstract][Full Text] [Related]
4. [Cardiovascular action of aldosterone].
Miyamori I; Kawai Y; Fan CY
Nihon Rinsho; 2006 Jul; 64 Suppl 5():40-5. PubMed ID: 16895168
[No Abstract] [Full Text] [Related]
5. Effect of aldosterone and MR blockade on the brain and the kidney.
Stier CT; Rocha R; Chander PN
Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
[TBL] [Abstract][Full Text] [Related]
6. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
Brown NJ
Nat Rev Nephrol; 2013 Aug; 9(8):459-69. PubMed ID: 23774812
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone, a new selective aldosterone blocker.
McMahon EG
Curr Pharm Des; 2003; 9(13):1065-75. PubMed ID: 12678858
[TBL] [Abstract][Full Text] [Related]
9. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone and end-organ damage.
Brown NJ
Curr Opin Nephrol Hypertens; 2005 May; 14(3):235-41. PubMed ID: 15821416
[TBL] [Abstract][Full Text] [Related]
11. The renal effects of mineralocorticoid receptor antagonists.
Bianchi S; Batini V; Bigazzi R
Int J Cardiol; 2015 Dec; 200():20-4. PubMed ID: 26049733
[TBL] [Abstract][Full Text] [Related]
12. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
Struthers AD; MacDonald TM
Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone as a mediator in cardiovascular injury.
Stier CT; Chander PN; Rocha R
Cardiol Rev; 2002; 10(2):97-107. PubMed ID: 11895576
[TBL] [Abstract][Full Text] [Related]
14. Future drug discovery in renin-angiotensin-aldosterone system intervention.
Tamargo M; Tamargo J
Expert Opin Drug Discov; 2017 Aug; 12(8):827-848. PubMed ID: 28541811
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
16. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology.
Jaisser F; Farman N
Pharmacol Rev; 2016 Jan; 68(1):49-75. PubMed ID: 26668301
[TBL] [Abstract][Full Text] [Related]
17. [Pathophysiological role of aldosterone in acute renal failure].
Bobadilla NA
Rev Invest Clin; 2007; 59(6):470-80. PubMed ID: 18402339
[No Abstract] [Full Text] [Related]
18. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
Mervaala EM; Malmberg L; Teräväinen TL; Laakso J; Vapaatalo H; Karppanen H
Br J Pharmacol; 1998 Jan; 123(2):195-204. PubMed ID: 9489606
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular benefits of aldosterone receptor antagonists.
Williams GH
Climacteric; 2003 Oct; 6 Suppl 3():29-35. PubMed ID: 15018246
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone blockade in CKD: emphasis on pharmacology.
Schwenk MH; Hirsch JS; Bomback AS
Adv Chronic Kidney Dis; 2015 Mar; 22(2):123-32. PubMed ID: 25704349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
